Altimmune
Stock Forecast, Prediction & Price Target
Altimmune Financial Estimates
Altimmune Revenue Estimates
Altimmune EBITDA Estimates
Altimmune Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $4.41M N/A | $-68K -101.54% | $426K 726.47% | Avg: $25M Low: $25M High: $25M avg. 5768.54% | Avg: $3.05M Low: $3.05M High: $3.05M avg. -87.8% | Avg: $55.21M Low: $55.21M High: $55.21M avg. 1710.42% | Avg: $616.48M Low: $616.48M High: $616.48M avg. 1016.44% |
Net Income
% change YoY
| $-96.17M N/A | $-84.71M 11.91% | $-88.44M -4.40% | Avg: $-141.60M Low: $-108.62M High: $33.54M avg. -60.09% | Avg: $-180.18M Low: $-119.27M High: $-76.14M avg. -27.24% | Avg: $-74.72M Low: $-74.72M High: $-74.72M avg. 58.53% | Avg: $158.14M Low: $158.14M High: $158.14M avg. 311.63% |
EBITDA
% change YoY
| $-85.71M N/A | $-84.90M 0.94% | $-87.93M -3.57% | Avg: $-15M Low: $-15M High: $-15M avg. 82.94% | Avg: $-1.83M Low: $-1.83M High: $-1.83M avg. 87.8% | Avg: $-33.13M Low: $-33.13M High: $-33.13M avg. -1710.42% | Avg: $-369.88M Low: $-369.88M High: $-369.88M avg. -1016.44% |
EPS
% change YoY
| -$2.33 N/A | -$1.81 22.31% | -$1.66 8.28% | Avg: -$1.26 Low: -$2.04 High: $0.63 avg. 24.09% | Avg: -$1.78 Low: -$2.24 High: -$1.43 avg. -40.87% | Avg: -$1.4 Low: -$1.4 High: -$1.4 avg. 20.93% | Avg: $2.97 Low: $2.97 High: $2.97 avg. 311.63% |
Operating Expenses
% change YoY
| $89.95M N/A | $87.67M -2.53% | $96.35M 9.90% | Avg: $-1.01B Low: $-1.01B High: $-1.01B avg. -1152.47% | Avg: $-123.72M Low: $-123.72M High: $-123.72M avg. 87.80% | Avg: $-2.23B Low: $-2.23B High: $-2.23B avg. -1710.42% | Avg: $-25.00B Low: $-25.00B High: $-25.00B avg. -1016.44% |
FAQ
What is Altimmune stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 70.70% in 2025-2028.
We have gathered data from 5 analysts. Their low estimate is -108.62M, average is -141.60M and high is 33.54M.
What is Altimmune stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 2101.90% in 2025-2028.
We have gathered data from 4 analysts. Their low revenue estimate is $25M, average is $25M and high is $25M.
What is Altimmune stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 78.95% in 2025-2028.
We have gathered data from 5 analysts. Their low earnings per share estimate is -$2.04, average is -$1.26 and high is $0.63.
What is the best performing analyst?
In the last twelve months analysts have been covering Altimmune stock. The most successful analyst is Patrick Trucchio.